Sign In

Corey McCann

CE🍐 at Pear Therapeutics

Dr. Corey M McCann, MD, PhD, is the President and CEO of Pear Therapeutics, a company dedicated to developing Prescription Digital Therapeutics (PDTs) to treat severe medical conditions.

Under Dr. McCann's leadership, Pear Therapeutics is at the forefront of redefining medicine by creating clinically validated software-based therapeutics that offer better outcomes for patients, engagement tools for clinicians, and cost-effective solutions for payers.

With an impressive pipeline of products and product candidates spanning various therapeutic areas, including PDTs for substance use disorder, opioid use disorder, and chronic insomnia, Pear is revolutionizing healthcare with innovative solutions.

Before his role at Pear Therapeutics, Corey McCann gained valuable experience as an investor at MPM Capital, advising on healthcare investments and managing partnerships, and as an Engagement Manager at McKinsey & Company focusing on life science technologies.

Dr. McCann's extensive educational background includes a Visiting Fellow position in Molecular and Cellular Biology at Harvard University, a MD/PhD in Neuroscience from Washington University in St. Louis, and a Bachelor of Science in Biology from Penn State University.

In addition to his role at Pear Therapeutics, Corey McCann is involved as a co-founder, advisor, or board member in several healthcare companies, showcasing his broad impact and influence within the industry.

His research and post-doctoral work have centered around molecular biology of synapses, brain imaging techniques, and the visualization of the brain, demonstrating a deep commitment to advancing medical science and technology.

Dr. McCann's academic achievements include graduating summa cum laude from Penn State University as an Evan Pugh Scholar, with a BS in Biology and minors in neuroscience, biochemistry, and molecular biology, highlighting his exceptional dedication to academic excellence.

Highlights

Dec 13 · linkedin

I am thrilled to end 2023 with some good news.

Today, we announced investment into the virtual addiction provider, PursueCare. In addition, PursueCare will also acquire the FDA-approved software-based medicines for addiction that were previously developed by Pear Therapeutics.

PursueCare already has extensive experience deploying these products and I am thrilled to put them back in patient’s hands. The combination of digital therapeutics and remote care has the opportunity to address the country’s addiction epidemic, dramatically improve health outcomes, and reduce healthcare costs.

Here’s to PursueCare and their patients. And to the future of software-based medicines!

https://lnkd.in/eH8ts7ZM.

Apr 7 · linkedin

Today is a difficult day for Pear Therapeutics. We announced that Pear voluntarily filed for Chapter 11 and will seek to sell assets through a sales process. We also announced a reduction in force, including me. This is certainly not the outcome I envisioned when I founded Pear in 2013.

I want to take this opportunity to sincerely thank our departing Pear employees. The Pear team has accomplished a lot together in bringing the first Prescription Digital Therapeutics (PDTs) to market. We’ve shown that clinicians will readily prescribe PDTs. We’ve shown that patients will engage with the products. We’ve shown that our products can improve clinical outcomes. We’ve shown that our products can save payors money. Most importantly, we’ve shown that our products can truly help patients and their clinicians.

But that isn’t enough. Payors have the ability to deny payment for therapies that are clinically necessary, effective, and cost-saving.  In addition, market conditions over the last two years have challenged many growth-stage companies, including us.

I want to personally thank each and every one of our employees for all that they’ve done for Pear and for patients. You are brave, talented, hard-working, mission-driven people and one of my greatest privileges has been to work by your side. I hope that this news doesn’t lessen your enthusiasm to innovate for patients.

A request for my LinkedIn network, as you see this, I highly recommend you connect with Pear alumni today to realize the tremendous benefits of having them join your team.

Here’s to the future of digital medicine that we’ve worked so hard to create.

Corey McCann
Add to my network

Location

San Francisco, California